quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:14:48·2h
FDARegulatory
Biogen Inc. logo

FDA Approval for ZURZUVAE issued to BIOGEN INC

BIIB· Biogen Inc.
Health Care
Original source

Companies

  • BIIB
    Biogen Inc.
    Health Care

Recent analyst ratings

  • Apr 22UpdateUBS$225.00
  • Apr 20UpdateWells Fargo$250.00
  • Apr 14UpdatePiper Sandler$214.00
  • Feb 20UpdateBarclays$185.00
  • Feb 9UpdateH.C. Wainwright$228.00
  • Jan 7UpdateUBS$185.00

Related

  • ANALYST1d
    Biogen upgraded by UBS with a new price target
  • ANALYST3d
    Biogen upgraded by Wells Fargo with a new price target
  • PR3d
    TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
  • PR3d
    Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
  • ANALYST9d
    Biogen upgraded by Piper Sandler with a new price target
  • PR15d
    Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
  • PR16d
    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
  • SEC17d
    Biogen Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022